Subgroup analysis revealed that this increase is only significant for hormone receptor-positive cancers and not for hormone receptor-negative cancers (HR 1.8, 95% CI 1.15-2.82, p = 0.010; versus HR 1.19, 95% CI 0.80-1.77, p = 0.390) (Poggio et al., 2022). This evidence concerns the gene NR4A1 and cancer.